Immatics reported FY 2025 revenue from collaboration agreements of EUR 48.3 million, R&D expenses of EUR 183.8 million and G&A expenses of EUR 51.2 million. The company posted a FY 2025 net loss of EUR 196.4 million (basic and diluted loss per share: EUR 1.61) and ended FY 2025 with cash and cash equivalents of EUR 345.9 million and other financial assets of EUR 123.4 million. On the business side, Immatics said its global Phase 3 SUPRAME trial of anzu-cel (IMA203) in previously treated advanced cutaneous melanoma remains on track, with interim and final analyses expected to be triggered in 2026, BLA submission expected in 1H 2027 and commercial launch planned for 2H 2027. The FDA granted Orphan Drug Designation for anzu-cel in cutaneous and uveal melanoma, and the company highlighted ongoing work across its PRAME franchise, including a planned 1H 2026 Phase 1a data update for IMA203CD8 (GEN2) focused on ovarian cancer and a 2H 2026 RP2D determination and Phase 1 update for the IMA402 PRAME bispecific. Immatics also noted a Phase 1 IMA402/IMA401 bispecific combination trial in sqNSCLC is expected to start in 2026, and said the first patient was dosed in 3Q 2025 in a Phase 1 anzu-cel plus Moderna’s mRNA-4203 combination study; it also reported receiving a USD 5 million milestone payment in January 2026 tied to an expanded Moderna TCER collaboration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050700PRIMZONEFULLFEED1001168421) on March 05, 2026, and is solely responsible for the information contained therein.
Comments